Advertisement
 
News
Subscribe to Drug Discovery & Development News

The Lead

EC, FDA Give Orphan Status to Boehringer’s New Leukemia Drug

April 17, 2014 | Comments

Boehringer Ingelheim Pharmaceuticals announced that the FDA and European Commission have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML). Read more...                   

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

NIH Awards Scripps $2M to Design a Better Diabetes Drug Model

April 17, 2014 1:21 pm | Comments

Scientists from the Florida campus of TSRI have been awarded $2.1 million from the NIH to study the therapeutic potential of safer and more effective alternatives to the current crop of anti-diabetic drugs, which have been limited in their use due to side effects including bone loss and CHF. Read more...

TOPICS:

Finding Suggests New Possibilities for Oncology and Virology

April 17, 2014 1:06 pm | Comments

Scientists at Washington University School of Medicine in St. Louis have uncovered a new way the immune system may fight cancers and viral infections, which could aid efforts to use immune cells to treat illness. Read more...     

TOPICS:

Sanguine, Mayo Clinic Agreement Furthers Personalized Medicine

April 17, 2014 12:40 pm | Comments

Sanguine announced an agreement with Mayo Clinic Bioservices, under which Mayo Clinic Bioservices will process, store and ship biospecimens that Sanguine has collected. Read more...                   

TOPICS:
Advertisement

New Gene Technology Has Therapeutic Implications

April 17, 2014 12:16 pm | Comments

For thousands of years humans have been tinkering with plant genetics, even when they didn’t realize that is what they were doing, in an effort to make stronger, healthier crops that endured climates better, and produced more. Read more...   

TOPICS:

VentiRx Completes Enrollment in Study of Orphan Cancer Drug

April 17, 2014 11:47 am | Comments

VentiRx Pharmaceuticals Inc. announced that enrollment has been completed in a Phase 2 trial of VTX-2337 in combination with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy. Read more...

TOPICS:

GSK Reports More Bribery Inquiries

April 17, 2014 11:24 am | Comments

British drugmaker GlaxoSmithKline is looking into allegations of bribery within its operations in Jordan and Lebanon. The company is also facing a corruption investigation in China and a bribery investigation in Poland and is looking into alleged bribery in Iraq. Read more...

TOPICS:

HPV Vaccine Works in HIV+ Women

April 16, 2014 2:00 pm | Comments

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial, countering doubts about whether the vaccine would be helpful. Read more...

TOPICS:

Phase 1 Results Positive for Tumor Vaccine

April 16, 2014 2:00 pm | Comments

Celldex Therapeutics Inc. announced that final data from its Phase 1 study of CDX-1401 (an off-the-shelf vaccine that targets dendritic cells) in solid tumors, including long-term patient follow-up, have been published in Science Translational Medicine. Read more...

TOPICS:
Advertisement

Measles Drug Lowers Viral Load

April 16, 2014 2:00 pm | Comments

A novel antiviral drug may protect people infected with the measles from getting sick and prevent them from spreading the virus to others, an international team of researchers said. Read more...                  

TOPICS:

Small Molecule Shows Potential in Advanced Cancers

April 16, 2014 1:34 pm | Comments

Cleveland BioLabs Inc. announced the achievement of all objectives in a Phase 1 clinical trial of CBL0102, or quinacrine, an orally administered small molecule in patients with advanced cancers for which no standard care exists or which had become resistant to conventional therapies. Read more...

TOPICS:

Baxter's Orphan Drug Candidate Hits Key Phase 3 Endpoint

April 16, 2014 1:06 pm | Comments

Baxter International Inc. announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics of BAX 111, a recombinant von Willebrand factor under investigation for the treatment of bleeding episodes in patients with von Willebrand disease. Read more...

TOPICS:

Recall Hurts Abbott, But Q1 Expectations Topped

April 16, 2014 1:00 pm | Comments

Abbott Laboratories' first-quarter net income tumbled 31% on unfavorable currency exchanges and a supplier recall that lowered sales of its baby formula, but the company beat most expectations and shares edged higher in early trading Wednesday. Read more...

TOPICS:

Researchers ID New Formulation for Cancer Treatment

April 16, 2014 11:20 am | Comments

Researchers have discovered a new way to deliver a tricky drug, dichloroacetate, that may one day make it a viable treatment for numerous forms of cancer. Read more...                       

TOPICS:

3-D Printed Tissues May Aid Drug Delivery, Wound Healing

April 16, 2014 11:13 am | Comments

A University of Oxford spin-out, OxSyBio, will develop 3-D printing techniques to produce tissue-like synthetic materials for wound healing and drug delivery. Read more...                       

TOPICS:

Drug Developers Using New Models, Methods to Boost Clinical Success Rates

April 16, 2014 11:05 am | Comments

Drug companies and their development partners who are seeking to increase clinical success rates of new drug candidates are developing tools to help them predict the likelihood of marketing approval and incorporating business planning earlier in clinical development, according to new evidence. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading